LIA
ASBPW

Limestone Investment Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Limestone Investment Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25K Hold
75,000
– – ﹤0.01% 396
2025
Q4 		$1.24K Hold
75,000
– – ﹤0.01% 439
2025
Q3 		$2.24K Hold
75,000
– – ﹤0.01% 515
2025
Q2 		$3.35K Buy
+75,000
New +$3.71K ﹤0.01% 472

Other funds holding ASBPW

MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Limestone Investment Advisors's ASBPW Position: Q1 2026 in Review

Limestone Investment Advisors held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 75,000 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #396.

Limestone Investment Advisors first reported a position in ASBPW in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.35K in Q2 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

  • Limestone Investment Advisors held 75,000 shares of Aspire Biopharma Warrant worth $1.25K as of Q1 2026.
  • Limestone Investment Advisors left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Limestone Investment Advisors's portfolio in Q1 2026, its #396 holding.
  • Limestone Investment Advisors first reported a position in Aspire Biopharma Warrant in Q2 2025 and has held it in 4 quarters since.
  • Limestone Investment Advisors's Aspire Biopharma Warrant position peaked at $3.35K in Q2 2025.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on Limestone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.